MedPath

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Registration Number
NCT05183347
Lead Sponsor
Boehringer Ingelheim
Brief Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male Japanese subjects following oral administration of single rising doses and multiple doses.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
36
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SRD: Dose Group 1BI 1291583SRD: single-rising dose
SRD: Dose Group 2BI 1291583SRD: single-rising dose
MD: Dose Group 4BI 1291583MD: multiple doses
PlaceboPlacebo-
SRD: Dose Group 3BI 1291583SRD: single-rising dose
Primary Outcome Measures
NameTimeMethod
Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigatorup to 65 days
Secondary Outcome Measures
NameTimeMethod
SRD: Area under the concentration-time curve of BI 1291583 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)up to 29 days

SRD: single-rising dose

MD: After the last dose: Maximum measured concentration of BI 1291583 in plasma at steady state (Cmax,ss)at day 28

MD: multiple doses

SRD: Maximum measured concentration of BI 1291583 in plasma (Cmax)up to 29 days

SRD: single-rising dose

MD: After the first dose: Area under the concentration-time curve of BI 1291583 in plasma over a uniform dosing interval τ (AUCτ,1)up to 24 hours

MD: multiple doses

MD: After the first dose: Maximum measured concentration of BI 1291583 in plasma (Cmax,1)up to 24 hours

MD: multiple doses

MD: After the last dose: Area under the concentration-time curve of BI 1291583 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)at day 28

MD: multiple doses

Trial Locations

Locations (1)

SOUSEIKAI Sumida Hospital

🇯🇵

Tokyo, Sumida-ku, Japan

© Copyright 2025. All Rights Reserved by MedPath